CurifyLabs

Meet us at Pharmanology today in Antwerpen, Belgium!

Meet us at expopharm in Munich today!

Läkartidningen is a prominent Swedish medical journal and news outlet targeted at healthcare professionals, particularly doctors and medical researchers. Patrick Ekstrand wrote this article and here's a few quotes translated to English: "In addition to producing tablets, capsules, and suppositories for medications that are no longer sold or for dosages that have been discontinued because manufacturers consider the market too small, she says there are other advantages to 3D-printed medications. 'The old technology is cumbersome, using large machines that produce at least 100 tablets at a time. With 3D printing, you can manufacture just one tablet if needed. The technology is simpler, more precise, and eliminates the risks associated with human error.' An integrated analysis method shows the amount of the active substance per tablet or capsule directly during production, something that was not previously possible." (Nicky Nadem AtrimusRx AB) "3D printing is very interesting for our work, as we focus on customized medications in small volumes. A patient can receive the exact dose of their medication, and healthcare staff, as well as parents of seriously ill children, don’t need to crush and measure out the medication to achieve an adjusted, lower dose," says Christina Holmberg, project manager for the implementation of 3D printing of medications at APL (Apotek Produktion & Laboratorier AB), according to the press release. "Another example is that you can adapt the form of the medication, so the patient can receive either a chewable or orally dissolvable tablet, or a tablet that completely dissolves in water and can be administered through a feeding tube," she adds. #Medicinemadepersonal

We had the pleasure of attending an impactful event hosted by AtrimusRx AB at the Grand Hotel in Stockholm. The gathering brought together a large audience from the industry to explore how innovative automated manufacturing methods, inspired by 3D printing, are shaping the future of personalized medicine. AtrimusRx plays a crucial role in supplying hospitals, pharmacies, and patients with unlicensed medicines—critical treatments not commercially available due to shortages or de-registrations. These include alternatives to medications in short supply, newly approved cancer treatments not yet launched in specific markets, and customized medicines for the elderly or children with specific needs. The event highlighted the pioneering work of CurifyLabs, with founders Charlotta Topelius and Niklas Sandler presenting their Pharma Kit technology. Participants had the opportunity to engage with this breakthrough by testing placebo chewable tablets produced through the technology. AtrimusRx continues to address the growing global issue of medicine shortages by offering solutions such as compounding to meet urgent medical needs. Special thanks to Nicky Nadem for organizing this important and insightful event! #manufacturingpersonalizedmedicine #CurifyLabs European Innovation Council and SMEs Executive Agency (EISMEA)

It’s time for Gerpac! Great to see scientific presentations on our technology from CHU d'Angers and CHUV | Lausanne university hospital. Meet us live at booth 39. #GERPAC

We interviewed Antoine Pierrot, a compounding pharmacist at CHUV | Lausanne university hospital about the Pharma Kit. CHUV, ranked among the world's top hospitals, is pioneering the use of our automated compounding technology, allowing for faster, more efficient production of patient-specific medications. Key benefits: 💊 Tailored treatments for children and elderly patients, making medicines easier to take and improving health outcomes. 🌍 A promising future for manufacturing personalized medicine through collaboration with doctors, ensuring the best care for every patient. Innovations like these are revolutionizing healthcare, making precision and patient-centric care the new standard! #HealthcareInnovation #PersonalizedMedicine #CurifyLabs #CHUV #PharmacyTech #PatientCare

Our CTO Niklas Sandler was invited to speak at ICCPC International Conference on Contemporary Pharmacy Challenges in Krakow today about the future of personalised medicine manufacturing. Our world tour continues!

🌟 News from IPTS 2024! 🌟 Our CTO and Founder, Niklas Sandler, had the honor of presenting at the 21st International Pharmaceutical Technology Symposium (IPTS) 2024 in Ankara, Turkey. His talk, titled "Automation of Personalized Medicine Manufacture in Pharmacies and Hospital Pharmacies," highlighted the critical role automation will play in shaping the future of healthcare and especially the manufacture of personalised medicines. This year's conference, themed "Next Generation Pharmaceutical Dosage Forms: The Future of Healthcare," focused on cutting-edge advancements such as innovative drug delivery systems, mRNA and DNA vaccines, advanced technologies in pharmaceutics, and the use of AI in drug design. Niklas' insights were well-received.´ Thanks to the organizers at Hacettepe University Faculty of Pharmacy for the invitation and for hosting such a prestigious and impactful event. Thank you Erem Bilensoy and colleagues! #IPTS2024 #PharmaceuticalTechnology #PersonalizedMedicine #Automation #HealthcareInnovation #NextGenHealthcare #FutureOfMedicine

Partnership Announcement! APL (Apotek Produktion & Laboratorier AB), one of the largest manufacturers of extemporaneous medicines and a leading contract development and manufacturing organization (CDMO) in Sweden, has joined forces with CurifyLabs, to improve the administration of medicines to children and critically ill patients using novel 3D printing technology. Erik Haeffler, Chief Executive Officer at APL, said, “We are very impressed with CurifyLabs’ commitment to supporting us on our journey to address the urgent unmet needs of critically ill patients. 3D printing is an exciting technology that is well-suited to extemporaneous manufacturing. It will give us additional opportunities to fulfill our public policy assignment.” “APL has demonstrated its strong capabilities in extemporaneous medicines with high quality and consistency, which will be critical to accelerating our development efforts together. We look forward to combining our strengths to create even greater value for patients needing personalized medicines,” added Charlotta Topelius, Chief Executive Officer at CurifyLabs. APL expects to provide fully compliant and validated 3D-printed extemporaneous medicines to the Swedish market by 2025, with the first 3D printers to be delivered in September 2024. #Manufacturingpersonalizedmedicines #automatedcompounding https://hubs.li/Q02NM5_K0

Mayo Clinic is known for being one of the best hospitals in the world and we are thrilled to be part of this program!